Evidence map›Paper›PMID 37471501›Full record

GuidelineCirculation2023

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.

Salim S Virani, L Kristin Newby, Suzanne V Arnold, Vera Bittner, LaPrincess C Brewer, Susan Halli Demeter, Dave L Dixon, William F Fearon, Beverly Hess, Heather M Johnson and 18 more

Erratum issued 5 registry-linked trialsAbstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Circulation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 5 registered trials, which are not on this map. Cited by 855 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
855citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06604117 recruitingstarted 2024, after this paper: background citation

A Prospective, Open-label Study Evaluating the Effects of Probucol Combined with Statins on Atherosclerotic Characteristics and Prognosis in Patients with Ischemic Stroke

Ran2024Enrolled200Registered outcomes6Posted comparisons0ConditionsAtherosclerosis of Artery, Ischemic Stroke, Lipid Disorder, StatinArmsProbucol, Statin
PMID 35583875PMID 35508321PMID 33883728PMID 35143758PMID 34487721PMID 34024117PMID 33867420PMID 32336234PMID 29115480PMID 26892955PMID 21852751PMID 21747278other papers from this trial
Open the trial in the graph
NCT06863545 narecruitingstarted 2025, after this paper: background citation

Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography

Ran2025Enrolled3,596Registered outcomes11Posted comparisons0ConditionsCardiovascular Events, Coronary Artery Disease, CT Angiography, PCSK9ArmsPCSK9 inhibitors and background lipid-modifying therapy, Standard lipid-modifying therapy
PMID 30403574PMID 28304224PMID 36222756PMID 36053504PMID 35368058PMID 31097161PMID 30678759PMID 30145934PMID 29322167PMID 27846344PMID 12800406PMID 37647074other papers from this trial
Open the trial in the graph
NCT06471036 narecruitingnot on this mapstarted 2024, after this paper: background citation

Test 2 Treat: A Randomized Implementation Trial to Improve LDL-C Management After Hospitalization for ASCVD (Atherosclerotic Cardiovascular Disease)

TypeinterventionalSponsorDuke UniversityRan2024 to 2027Enrolled400ConditionsASCVD, LDL-CArmsCare Champion Intervention
NCT07314138 narecruitingnot on this mapstarted 2026, after this paper: background citation

MICRA-HYBRID Trial: A Randomized Controlled Trial of 'Multivessel Minimally Invasive Coronary Bypass Grafting as HYBRID Revascularization Versus Conventional Off-Pump Coronary Artery Bypass Grafting'

TypeinterventionalSponsorCatharina Ziekenhuis EindhovenRan2026 to 2034Enrolled250ConditionsCoronary Artery Disease (CAD), Bypass, Cardiopulmonary, Minimally Invasive Coronary Revascularization Surgery, Off-pump Coronary Artery BypassArmsMultivessel Hybrid Coronary Revascularization, Off-pump coronary arterial bypass grafting (OPCAB)
NCT07687706 phase3recruitingnot on this mapstarted 2026, after this paper: background citation

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Superiority, Investigator-initiated Trial of Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)

TypeinterventionalSponsorHanyang University Guri HospitalRan2026 to 2027Enrolled1,524ConditionsIschemic Stroke, Ischemic Stroke, Acute, Transient Ischemic Attack (TIA), Cerebrovascular DiseaseArmsTegoprazan 50 mg, Placebo
3 · Its place in the literature

Who cites it

855 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

795 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Salim S ViraniACC/AHA representative.
L Kristin NewbyACC/AHA representative.
Suzanne V Arnold
Vera BittnerNational Lipid Association representative.
LaPrincess C Brewer
Susan Halli DemeterPreventive Cardiovascular Nurses Association representative.
Dave L DixonFormer Joint Committee on Clinical Practice Guideline member; current member during the writing effort.
William F FearonSociety for Cardiovascular Angiography and Interventions representative.
Beverly HessPatient representative/lay stakeholder.
Heather M JohnsonAmerican Society for Preventive Cardiology representative.
Dhruv S Kazi
Dhaval KolteAHA/ACC Joint Committee on Clinical Data Standards.
Dharam J Kumbhani
Jim LoFasoPatient representative/lay stakeholder.
Dhruv Mahtta
Daniel B MarkFormer Joint Committee on Clinical Practice Guideline member; current member during the writing effort.
Margo Minissian
Ann Marie Navar
Amit R Patel
Mariann R PianoFormer Joint Committee on Clinical Practice Guideline member; current member during the writing effort.
Fatima Rodriguez
Amy W TalbotACC/AHA representative.
Viviany R Taqueti
Randal J Thomas
Sean van Diepen
Barbara WigginsAmerican College of Clinical Pharmacy representative.
Marlene S WilliamsAHA/ACC Joint Committee on Performance Measures.
Peer Review Committee Members

Funding

SURPASS: (Statin Use and Risk Prediction of Atherosclerotic Cardiovascular Disease in minority Subgroups)K01HL144607 · NHLBI · STANFORD UNIVERSITY · PI RODRIGUEZ, FATIMA · 2019 to 2023
$856k
NHLBI NIH HHS K01 HL144607
6 · The paper itself

Abstract

aimThe "2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease" provides an update to and consolidates new evidence since the "2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease" and the corresponding "2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease."

methodsA comprehensive literature search was conducted from September 2021 to May 2022. Clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants were identified that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE: This guideline provides an evidenced-based and patient-centered approach to management of patients with chronic coronary disease, considering social determinants of health and incorporating the principles of shared decision-making and team-based care. Relevant topics include general approaches to treatment decisions, guideline-directed management and therapy to reduce symptoms and future cardiovascular events, decision-making pertaining to revascularization in patients with chronic coronary disease, recommendations for management in special populations, patient follow-up and monitoring, evidence gaps, and areas in need of future research. Where applicable, and based on availability of cost-effectiveness data, cost-value recommendations are also provided for clinicians. Many recommendations from previously published guidelines have been updated with new evidence, and new recommendations have been created when supported by published data.

Indexed as

CardiologyCoronary DiseaseMyocardial IschemiaAmerican Heart AssociationHumansProliferating Cell Nuclear AntigenUnited StatesProliferating Cell Nuclear Antigenacute coronary syndromeAHA Scientific Statementsair pollutionanginaantiplatelet therapyaspirinatherosclerosisautoimmune diseasescardiac eventscardiac rehabilitationcardiovascular diseasescolchicinecoronary artery diseasecoronary diseasecost-benefit analysisdepressiondiabetesdietdietary supplementsdiet therapydrug therapydual antiplatelet therapyenvironmental exposureexercise tolerancefactor Xa inhibitorsfibrinolytic agentsglucagon-like peptide-1 receptor agonistsguideline-directed management and therapyhealth care outcome assessmentshealth equityheart disease risk factorsheart failurehormone replacement therapyhypercholesterolemiahypertensionimmunizationischemic heart diseasemental healthmultidisciplinarymyocardial ischemiaoutcomesoutpatientpatient care teampharmacologypregnancyproton pump inhibitorsquality of lifesafetysecondary preventionsexual behaviorsexual healthshared decision-makingsmoking cessationsocial determinants of healthsodium-glucose cotransporter 2 inhibitorsspontaneous coronary artery dissectionstresstherapeutic usetherapytype 2 diabetesvaccination

Identifiers

PMID37471501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.